Pyruvate kinase modulators as a therapy target: an updated patent review 2018–2023

Sevki Adem,Azhar Rasul,Saba Riaz,Ayesha Sadiqa,Matloob Ahmad,Muhammad Shahid Nazir,Mudassir Hassan
DOI: https://doi.org/10.1080/13543776.2024.2403616
2024-09-22
Expert Opinion on Therapeutic Patents
Abstract:Introduction Cancer cells adopt a glycolytic phenotype to fulfill their energy needs in unfavorable conditions. In metabolic rewiring, cancer cells upregulate the expression of glycolytic pathway regulators including glucose transporter 1, hexokinase 2, and PKM2 (pyruvate kinase) into its M2 splice form. Among these regulators, PKM2 plays a major role in metabolic reprogramming and is overexpressed in various diseases, including cancer. Dimerization of PKM2 causes the generation of synthetic precursors from glycolytic intermediates, which are essential for cellular growth and cancer cell proliferation.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?